|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
NELFINAVIR SHOULD NOT BE COADMINISTERED WITH CISAPRIDE,ASTEMIZOLE,MIDAZOLAM,TRIAZOLAM OR ERGOT DERIVATIVES BECAUSE COMPITITION FOR CYP3A4 BY EFAVIRENZ MAY RESULT IN INHIBITION OF OTHER DRUGS METABOLISM LEADING TO SERIOUS SIDE EFFECTS LIKE ARRHYTHMIAS
|
NELFINAVIR SHOULD NOT BE COADMINISTERED WITH CISAPRIDE,ASTEMIZOLE,MIDAZOLAM,TRIAZOLAM OR ERGOT DERIVATIVES BECAUSE COMPITITION FOR CYP3A4 BY EFAVIRENZ MAY RESULT IN INHIBITION OF OTHER DRUGS METABOLISM LEADING TO SERIOUS SIDE EFFECTS LIKE ARRHYTHMIAS
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
INCREASED INCIDENCE OF SIDE EFFECTS ON CO-ADMINISTRATION
|
INCREASED SERUM CONCENTRATION OF AMIODARONE
|
CYCLOSPORINE WHEN CO-ADMINISTERED WITH HIV-PROTEASE INHIBITORS MAY LEAD TO MUTUAL INCREASE IN PLASMA CONCENTRATION
|
NELFINAVIR MAY INCREASE THE DRUG LEVELS TO TOXIC LIMITS DUE TO DECREASED METABOLISM
|
NELFINAVIR MAY INCREASE THE DRUG LEVELS TO TOXIC LIMITS DUE TO DECREASED METABOLISM
|
NELFINAVIR MAY INCREASE THE DRUG LEVELS TO TOXIC LIMITS DUE TO DECREASED METABOLISM
|
NELFINAVIR MAY INCREASE THE DRUG LEVELS TO TOXIC LIMITS DUE TO DECREASED METABOLISM
|
NELFINAVIR MAY INCREASE THE DRUG LEVELS TO TOXIC LIMITS DUE TO DECREASED METABOLISM
|
NELFINAVIR MAY INCREASE THE DRUG LEVELS TO TOXIC LIMITS DUE TO DECREASED METABOLISM
|
NELFINAVIR MAY INCREASE THE DRUG LEVELS TO TOXIC LIMITS DUE TO DECREASED METABOLISM
|
NELFINAVIR MAY INCREASE THE DRUG LEVELS TO TOXIC LIMITS DUE TO DECREASED METABOLISM
|
CO-ADMINISTRATION WITH ANTI-RETROVIRAL DRUGS MAY LEAD TO INCREASED CLEARANCE OF OTHER DRUG
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
CONCURRENT USE WITH ASTEMIZOLE, REPORTED TO SIGNIFICANTLY ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
NELFINAVIR MAY CAUSE DECREASED AUC OF ZIDOVUDINE; ROUTINE DOSE MODIFICATION IS NOT WARRANTED
|
CONCURRENT USE WITH TERFENADINE, REPORTED TO SIGNIFICANTLY ALTER THE METABOLISM OF IT; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS, LIKE PROLONGED QT INTERVAL,CARDIAC ARREST,TORSADE DE POINTES,VENTRICULAR ARRHYTHMIAS, AND DEATH HAVE BEEN REPORTED
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|